FROM EXOSOMES HISTORY TO CILOA FIRST APPLICATIONS

While the interest of the scientific community explodes for exosomes, Ciloa has already developed a pioneering technology for more than 15 years. Ciloa’s technology is based on the production of fully native membrane proteins on exosomes in a natural way by cells.

These nano-vesicles produced by cells have long remained mysterious after their discovery in 1983. In 1996, exosomes were shown to be involved in the immune system. In 2007, exosomes were described to play major roles in intercellular communications.

Robert MAMOUN understood since the early 2000s the high potential of a bio-drug development technology through exosomes.

Even before the explosion of interest in exosomes, the 2 Ciloa patents were filed in 2008 and 2009. Several years were necessary to reach a true technological maturity allowing the development of antibody drug candidates, where we are today.

CILOA’S HISTORY IS DEEPLY CONNECTED TO RESEARCHES ON EXOSOMES

Ciloa’s history began a long time before “exosome explosion”, as shown below (number of publications about exosomes per year – US National Library of Medicine, National Institutes of Health).

OUR HISTORY AND THAT OF EXOSOMES

1996 > Exosomes essential for adaptive immune response

Dr. Graça Raposo published her discovery that immune cells such as B lymphocytes secrete exosomes, and that these vesicles carry membrane-bound molecules essential for the adaptive immune response. (Exosome Explosion” by Clotilde Théry | July 1, 2011)

AWARD-WINNING TECHNOLOGY

Ciloa won the OSEO – MESR Award of the ‘Emergence’ national competition for the creation of innovative companies and was twice nominated in the ‘Creation-Development’ category.

In 2013, Ciloa won the Innovation Award.

INNOVATION AWARD 2013

Robert MAMOUN receives the Innovation Award

Learn more on Transferts LR
Menu